Advisors Asset Management Inc. purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 44,013 shares of the biotechnology company's stock, valued at approximately $23,850,000. Advisors Asset Management Inc. owned approximately 0.10% of United Therapeutics at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in UTHR. BlackRock Inc. bought a new position in United Therapeutics in the 2nd quarter valued at $2,868,735,000. Jupiter Topco LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $450,140,000. Bank of New York Mellon Corp bought a new stake in shares of United Therapeutics during the 2nd quarter worth approximately $159,522,000. Caisse de depot et placement du Quebec bought a new position in United Therapeutics in the second quarter valued at about $154,304,000. Finally, Legal & General Group Plc bought a new stake in shares of United Therapeutics in the 2nd quarter valued at $112,209,000. 94.08% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of analysts have commented on the company. Morgan Stanley boosted their price objective on United Therapeutics from $515.00 to $566.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 7th. HC Wainwright assumed coverage on United Therapeutics in a report on Monday, November 9th. They set a "buy" rating and a $660.00 price objective for the company. The Goldman Sachs Group reissued a "sell" rating and issued a $368.00 price target on shares of United Therapeutics in a research report on Thursday, October 15th. Royal Bank Of Canada increased their price objective on United Therapeutics from $697.00 to $725.00 and gave the stock an "outperform" rating in a report on Thursday, November 5th. Finally, JPMorgan Chase & Co. reduced their target price on United Therapeutics from $710.00 to $695.00 and set an "overweight" rating for the company in a research report on Wednesday, October 28th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $676.40.
Read Our Latest Stock Report on UTHR
Trending Headlines about United Therapeutics
Investors following UTHR have been watching these headlines:
- Positive Sentiment: The first clinical UThymoKidney transplant advances United Therapeutics’ effort to develop an additional source of transplantable kidneys. Progress in the trial could support the long-term value of its xenotransplantation program, though clinical and regulatory risks remain. Article: First clinical xenotransplant in EXTEND study
- Neutral Sentiment: One article argues UTHR may be below fair value after the transplant announcement. That is an opinion-based valuation view, not a new financial forecast or clinical result. Article: UTHR may be below fair value
- Negative Sentiment: Recent insider-sale reports may weigh on sentiment: CEO Martine Rothblatt sold 5,410 shares for about $3.13 million, while EVP Paul Mahon sold 8,300 shares for about $4.69 million. Rothblatt retained 324,443 shares after her sale; the transactions alone do not establish a change in the company’s outlook. Article: CEO share sale
Insider Transactions at United Therapeutics
In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the firm's stock in a transaction on Thursday, November 19th. The stock was sold at an average price of $565.09, for a total transaction of $4,690,247.00. Following the completion of the transaction, the executive vice president owned 45,172 shares of the company's stock, valued at approximately $25,526,245.48. This trade represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher Patusky sold 1,210 shares of the business's stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $580.00, for a total transaction of $701,800.00. Following the sale, the director directly owned 2,140 shares in the company, valued at $1,241,200. The trade was a 36.12% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 408,148 shares of company stock valued at $220,922,751. Company insiders own 8.60% of the company's stock.
United Therapeutics Stock Performance
NASDAQ:UTHR opened at $554.73 on Friday. The firm has a market cap of $23.63 billion, a PE ratio of 20.93, a price-to-earnings-growth ratio of 3.91 and a beta of 0.49. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23. The business has a 50 day moving average price of $550.00 and a 200-day moving average price of $538.90.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The firm had revenue of $832.50 million for the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The business's revenue was up 4.1% on a year-over-year basis. During the same period last year, the company posted $7.16 earnings per share. Research analysts predict that United Therapeutics Corporation will post 25.08 EPS for the current year.
United Therapeutics announced that its Board of Directors has approved a stock repurchase plan on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This buyback authorization allows the biotechnology company to buy up to 8.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.
About United Therapeutics
(
Free Report)
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.